All News
Effective Treatments for Still's Disease
A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK).
Read Article
Depression and RA (3.8.2024)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week.
Read Article
Starting MTX at higher or subcut. doses yields better ACR20 responses. Review of 12 trials & 1,566 pts, shows:
- higher initial MTX 25 mg (but more GI AEs)
- SC MTX more ACR20 resp (85% vs PO 77%)
- MTX non-response, success w/ SC MTX
https://t.co/01PuDpkUIF https://t.co/vXLWEp4srH
Dr. John Cush RheumNow ( View Tweet)
Japanese study of 96 #SLE pregnancies: 59 in remission @ conception. Remission had fewer adverse preg outcomes (OR 0.27) vs those w/ activity. No difference in APO based on serologies, but Pred ≥7.5/d us had signif. more APO. (OR 3) https://t.co/BvOeiSERN9 https://t.co/ePh1dqdJvS
Dr. John Cush RheumNow ( View Tweet)
Polyarteritis Nodosa (PAN): Clinical Features and Outcomes
A multinational study of PAN through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).
https://t.co/cyCzxRnjJf https://t.co/DleD9cYFTb
Dr. John Cush RheumNow ( View Tweet)
Frensius-Kabi has announced that the FDA has approved the tocilizumab biosimilar, Tyenne (tocilizumab-aazg); the first TCZ biosimilar with both IV and subcutaneous formulations https://t.co/F3d8DKxpkU https://t.co/NSEqAcoBBo
Dr. John Cush RheumNow ( View Tweet)
Review article on inclusion body myositis, a progressive, debilitating myopathy w/ onset > 50 yrs. IBM typically has asmmetric, painless, weakness & atrophy of finger flexors or quadriceps w/ dysphagia. Most are wheelchair bound w/in 13-15 years https://t.co/LoWtmDqimu https://t.co/N3OUU7QMc1
Dr. John Cush RheumNow ( View Tweet)
The more you know, the more you realize how much you don’t know. The less you know, the more you think you know everything. Knowledge is humbling. Ignorance is arrogant.
Prof. Feynman ProfFeynman ( View Tweet)
Can Mycophenolate be Stopped in Stable SLE?
https://t.co/8oQx0cqDr3 https://t.co/mlt2Qqj8wm
Dr. John Cush RheumNow ( View Tweet)
COVIDs Extended Risk for Rheumatic Disease
Annals of Internal Medicine reports a large, binational study finding SARS-CoV-2 infection was associated with an increased risk for AIRDs that extends up to 12 months after infection.
https://t.co/HjQ56hiiny https://t.co/vvC3iVqNyF
Dr. John Cush RheumNow ( View Tweet)
Review of autoimmune Dz & adverse preg outcomes: Incr risk of:
- Miscarriage w/ Sjögrens (RR 8.85) & SLE (OR 4.9)
- Preeclampsia w/ SLE (OR 3.2)
- IUGR w/ scleroderma (OR 3.2) & celiac (OR 1.71)
- Preterm birth w/ SLE (OR 2.79).
https://t.co/bll2x2aS9Z https://t.co/Eg0sVBcPmR
Dr. John Cush RheumNow ( View Tweet)
Sandoz has announced FDA approval for their two interchangeable biosimilars of denosumab - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) based on reference products Xgeva and Prolia https://t.co/Spb0ABOMMm https://t.co/wkMurvB0G3
Dr. John Cush RheumNow ( View Tweet)
Lancet - Full Read Review of the Diagnosis and management of ANCA-associated vasculitis
by Stone, et al https://t.co/Lg0FKR8RZ4 https://t.co/RUpK00YmTh
Dr. John Cush RheumNow ( View Tweet)
Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity
#1 (24%) w/ RP-ILD & high mortality
#2 (14%) dermatomyositis, intermediate prognosis
#3 (62%) arthritis & mechanics hands, good prognosis https://t.co/4NqZp4yR18 https://t.co/rBrhBxxniR
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Community-Acquired Pneumonia (CAP)
https://t.co/AMConIb14r https://t.co/BCfcHc5i37
Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/a3XeAa2lcG https://t.co/dTZa2uQF97
Dr. John Cush RheumNow ( View Tweet)
Polyautoimmunity in RA, Regardless of ACPA Positivity
While it is believed that autoimmunity follows autoantibody positivity, a Danish study shows the incidence of polyautoimmunity to be similar in RA patients who are either ACPA + or -.
https://t.co/7lmp1NB0XX https://t.co/onaEluzkGy
Dr. John Cush RheumNow ( View Tweet)
19% Arthritis Prevalence in the US
According to NHIS, in 2022, the prevalence of diagnosed arthritis in adults was 18.9% . These numbers are down since the CDC's MMWR report of 2019–'21, where it was estimated 21.2% of U.S. adults had "diagnosed arthritis"
https://t.co/mtYSBHw8Oo https://t.co/NHqjLlwatm
Dr. John Cush RheumNow ( View Tweet)
Frensius-Kabi has announced that the FDA has approved the tocilizumab biosimilar, Tyenne (tocilizumab-aazg); the first TCZ biosimilar with both IV and subcutaneous formulations https://t.co/cdSVbuBzXf https://t.co/CUC5v0hSxr
Dr. John Cush RheumNow ( View Tweet)
Fibroblast activation w/ inflammatory arthritis studied by PET to detect fibroblast activation protein (FAP), but decreases after TNF or 17A inhib. Fibroblasts switch from pathogenic (MMP3+/IL6+) to pro-resolving phenotype (CD200+DKK3+) https://t.co/K1xAMqPiuT https://t.co/07NNgW9Lpv
Dr. John Cush RheumNow ( View Tweet)